» Download Public Reports
About 1 100 reports
- Country report
- April 2013
- 3 pages
March 2013
... And the website of the stock exchange of hong kong limited (- investors are advised to take due care to the investment risks. The board of guangzhou pharmaceutical company limited guangzhou ...
March 2013
... Are advised to take due care to the investment risks. The board of guangzhou pharmaceutical company limited guangzhou, the prc, 28 march 2013 as at the date of this announcement, the board of the company ...
March 2013
... In revenues last year, and earned $177.5 Million in net income. Its cro division generated 74% of its revenues. Also noted: quintiles helped develop or commercialize 85% of the central nervous system drugs ...
April 2013
... Including roche, a cancer drug with sales recently forecasted to $7 billion out to 2015; and tecfidera, the new multiple sclerosis drug that made it to market in less than a 3 week of being approved ...
April 2013
... Refund : after completion of phase ii trial, if jiangsu neptunus decides not to proceed with the next clinical trial by reason of safety and effectiveness of the recombinant technology, shenzhen neptunus ...
April 2013
... D productivity by shortening drug-development times and delivering the highest-quality services. We work with our customers to provide them with the capabilities and capacity they need throughout the drug ...
April 2013
... Med 2006;38:52-63 these features lead to type 2 diabetes and cardiovascular disease visceral obesity is associated with a cluster of metabolic abnormalities often described as the Metabolic syndrome ...
March 2013
... Permit to stabilize price of garlic jakarta, march 13th 2013 To control the price of garlic, the indonesian ministry of trade has taken concrete steps by issuing an import permit for the import ...
March 2013
... Step, if not to target (generally hba1c) consider first line consider second line consider third line consider fourth line or Or basal or premix qd/bid insulin secretagogue, gi ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 900 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Ostora (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Ostora (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
April 2013
$ 5 400
With the fast development of the plant extract industry, China is one of the major suppliers of plant extracts in the world, thanks to its advantages of abundant resources and traditional medicine culture. ...
March 2013
$ 4 995
PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market ...
